Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement...
Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement...
Arrowhead Pharmaceuticals宣佈了對ARO-CFb的1/2A期臨床研究的中期結果，該公司正在開發的RNA干擾（RNAi）療法，目標是補充因子b，作爲潛在的補充療法...
Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement Mediated Diseases
Arrowhead Pharmaceuticals宣佈了針對ARO-CFb的1/2A期臨床研究的中期結果，該研究是針對補體因子b的研究性RNA干擾(RNAi)治療，正在開發作爲補體介導疾病的潛在治療方法。
資訊熱榜
更新時間